Neuroscience discipline

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

4 days ago talkbio0Tagged AFFIRM-1 phase 3 trial, BNC210, Clinical trial failure, Discontinuation (procedure), Merck, Neuphoria, Neuroscience discipline, Partnership, Phobia, Social, Post-Traumatic Stress Disorder, Programs - Publication Format, Schizophrenia

Neuphoria Therapeutics; BNC210; social anxiety disorder; AFFIRM-1 phase 3 trial; clinical trial failure; program discontinuation; PTSD; Merck partnership; Minerva Neurosciences; schizophrenia therapy

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

1 month ago talkbio0Tagged alpha 1-antitrypsin, cardiometabolic, Eli, Eli Lilly, Generation Park, Houston, Immunology, Investments, Manufacturing, Neoplasms, Neuroscience discipline, pharmaceutical manufacturing, small molecule medicines

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience

AbbVie Buys Gilgamesh’s Psychedelic Drug Bretisilocin for $1.2B

2 months ago talkbio0Tagged AbbVie, Acquisition, bretisilocin, Dosage Forms, Gilgamesh, GM-2505, Hallucinogens, mental health, Neuroscience discipline

AbbVie; Gilgamesh Pharmaceuticals; psychedelic drug; bretisilocin; GM-2505; major depressive disorder; acquisition; mental health; neuroscience; pharmaceutical deal

Reunion Psychedelic Therapy Advances to Pivotal Trials after Postpartum Depression Success

2 months ago talkbio0Tagged Clinical Trials, Depression, Postpartum, Montgomery-Åsberg Depression Rating Scale, Montgomery-Asberg Depression Rating Scale Questionnaire, Neuroscience discipline, Phase 2 Clinical Trials, Phase 3 Clinical Trials, psychedelic therapy, RE104, RECONNECT, remission rates, Reunion

Reunion Neuroscience; RE104; psychedelic therapy; postpartum depression (PPD); Phase II trial; Phase III trial; RECONNECT trial; clinical trial results; Montgomery-Åsberg Depression Rating Scale (MADRS); remission rates

AbbVie Raises 2025 Guidance and Eyes Strategic Deals in Neuroscience, Obesity, and Oncology

3 months ago talkbio0Tagged AbbVie, Advice, earnings, Neuroscience discipline, Obesity, PD-1/VEGF, Strategic Deals

AbbVie; 2025 guidance; earnings; neuroscience; obesity; PD-1/VEGF; strategic deals; pharmaceuticals

Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

4 months ago talkbio0Tagged Blood - brain barrier anatomy, Brain Delivery Module, dealmaking, Eledon, Iambic, Neuroscience discipline, Novartis, Revolution Medicines, Sernova, Sironax

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

4 months ago talkbio0Tagged ALTO-203, Attention, Biological Markers, development aspects, drug activity, Electroencephalography, Neuroscience discipline, theta/beta ratio, Wakefulness, William Blair

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

AbbVie Commits $335M Upfront in Landmark siRNA Deal With ADARx

5 months ago talkbio0Tagged AbbVie, ADARx, biotech partnerships, Drug Development, Gene Silencing, Immunology, Neoplasms, Neuroscience discipline, RNA technology, RNA, Small Interfering

AbbVie; ADARx Pharmaceuticals; siRNA therapeutics; gene silencing; neuroscience; immunology; oncology; biotech partnerships; RNA technology; drug development